BPC-157 attenuated clopidogrel-induced gastric ulcer recurrence in rats by inhibiting ER stress-mediated cell death, reducing inflammation, and promoting blood vessel growth via the VEGF-A/AKT/p38 pathway.
Multiple pathwaysBPC-157 acted through ER stress inhibition, anti-inflammation, and angiogenesis promotion simultaneously
What the researchers found
BPC-157 attenuated clopidogrel-induced gastric mucosa injury by inhibiting ER stress-mediated apoptosis and inflammation while promoting angiogenesis via VEGF-A/VEGFR1-mediated AKT/p38/MAPK signaling. These effects were partially dependent on nitric oxide.
Why it matters
Millions of people take clopidogrel for cardiovascular protection but face gastric ulcer risks. BPC-157's multi-pathway gastroprotective mechanism could offer a targeted way to protect the stomach without compromising the blood thinner's cardiovascular benefits.
The numbers in context
BPC 157 significantly reduced gastric lesion area; L-NAME partially reversed BPC 157 protection.
How the study worked
Rat model with acetic acid-induced gastric ulcers followed by clopidogrel to trigger recurrence. Groups received clopidogrel alone, with BPC-157, or with L-NAME (NO blocker). Assessed using TUNEL assay, histology, immunohistochemistry, and Western blot for CHOP, VEGF-A, VEGFR1, and eNOS.
Who was studied
Sprague Dawley rats with acetic acid-induced gastric ulcers treated with clopidogrel
What this study cannot tell us
Animal study in rats — human dosing, safety, and efficacy are not established. The acetic acid ulcer model followed by clopidogrel may not perfectly replicate clinical ulcer recurrence in patients. BPC-157 is not yet approved for clinical use.
How to read the evidence
Preclinical animal study with detailed mechanistic analysis. Multiple pathways confirmed via Western blot and histology, but no human data available.
When this study was published
Published in 2020. BPC-157 research continues to expand in preclinical settings, though human clinical trials remain limited.
The bigger picture
BPC-157 continues to accumulate evidence as a multi-functional gastroprotective peptide. This study adds clopidogrel-induced injury to the list of gastric conditions where BPC-157 shows preclinical benefit, and importantly elucidates the molecular mechanisms involved.
Questions still open
- Would BPC-157 protect against gastric injury from other antiplatelet or anticoagulant drugs?
- What is the optimal dose and route of BPC-157 for gastroprotection in humans?
- Could BPC-157 be combined with clopidogrel clinically without affecting its antiplatelet efficacy?
Common questions
What is BPC-157?
Why does clopidogrel cause stomach problems?
Read the original research
Clopidogrel-Induced Gastric Injury in Rats is Attenuated by Stable Gastric Pentadecapeptide BPC 157.
Drug design, development and therapy, 14, 5599-5610
Citation
Wu, Hailu; Wei, Ming; Li, Nan; Lu, Qin; Shrestha, Sachin Mulmi; Tan, Jiacheng; Zhang, Zhenyu; Wu, Guoqiu; Shi, Ruihua. (2020). Clopidogrel-Induced Gastric Injury in Rats is Attenuated by Stable Gastric Pentadecapeptide BPC 157.. Drug design, development and therapy, 14, 5599-5610. https://doi.org/10.2147/DDDT.S284163